{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Viracta Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"VIRX"},"Address":{"label":"Address","value":"2533 SOUTH COAST HIGHWAY 101,SUITE 210, CARDIFF, California, 92007, United States"},"Phone":{"label":"Phone","value":"+1 858 400-8470"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants."},"CompanyUrl":{"label":"Company Url","value":"https://www.viracta.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Ayman El-Guindy","title":"Chief Scientific Officer"},{"name":"Darrel P. Cohen","title":"Chief Medical Officer"},{"name":"Donald Strickland","title":"VP-Clinical Development & Medical Director"},{"name":"Mark A. Rothera","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}